Head to head
Deep 6 AI vs Citeline
Patient-level record mining versus market-level trial data.
Deep 6 AI
Citeline
Model
Deep 6 AI
AI patient matchingCiteline
Data & intelligence platformIn one line
Deep 6 AI
Mines clinical records, including unstructured notes, to find eligible patients.Citeline
Trial intelligence and site/investigator data — not a recruitment vendor.What they do
Deep 6 AI
Applies natural language processing to health system records — notes, pathology, imaging reports — to surface patients who meet criteria that structured coding misses, then supports site-side outreach.Citeline
Supplies the industry's reference datasets on trials, sites, and investigators, used for feasibility, competitive landscape, and site selection. It informs enrollment planning rather than delivering patients.Pricing
Deep 6 AI
Enterprise software agreements with health systems and sponsors.Citeline
Enterprise data subscription, typically annual per-seat or per-module.Strengths
Deep 6 AI
- Finds patients invisible to ICD-code queries
- Publicly focused on oncology and other criteria-heavy indications
- Supports feasibility with counts from real records rather than estimates
Citeline
- Deepest commercial dataset on trial and investigator activity
- Essential for competitive-landscape and site-saturation analysis
Watch for
Deep 6 AI
- Value depends on your sites being connected health systems
- Identifying a patient is not consenting one; site outreach still has to happen
Citeline
- It is a subscription, not a solution — someone still has to act on it
- Cost is meaningful for a small biotech running one study
Best for
Deep 6 AI
Oncology and precision-medicine trials with complex eligibility criteria.Citeline
Feasibility and site selection teams who need landscape data before committing sites.Poor fit
Deep 6 AI
Studies at small independent sites without integrated record systems.Citeline
A sponsor whose actual problem is that sites already selected are not enrolling.When Deep 6 AI is the right call
Pick Deep 6 AI when you need to know which specific patients inside partnered health systems could meet criteria-heavy eligibility.
When Citeline is the right call
Pick Citeline when the question is landscape-level: who else is running trials in your indication, where the competing studies sit, and which investigators have track record.
How to actually decide
These answer different questions and are often bought together. Feasibility and site selection lean Citeline; identifying patients at an activated site leans Deep 6. Ask Deep 6 which health systems in your target geography are actually live — coverage, not the algorithm, determines whether it helps you.
Do not pick on capability decks. Give both the same brief — your protocol, your countries, your screen failure assumptions — and ask each for the referral-to- randomization ratio they achieved on the three most similar studies they have run. Then price both on cost per randomized patient. The comparison usually resolves itself at that point, and often reveals that neither is the problem: the enrollment assumptions in the protocol were wrong from the start.
Our sister publication Rock Enroll covers that diagnosis in depth for sponsors and CRO teams.